The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/-Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

被引：25
|
作者：
Serrano, Dolores [1 ]
Torrado, Susana [1 ]
Torrado-Santiago, Santiago [1 ]
Gisbert, Javier P. [2 ]
机构：
[1] Univ Complutense, Fac Farm, Dept Pharmaceut Technol, E-28040 Madrid, Spain
[2] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IP, Dept Gastroenterol, Madrid, Spain
来源：
CURRENT DRUG METABOLISM | 2012年 / 13卷 / 09期
关键词：
CYP2C19; genetic polymorphism; Helicobacter pylori eradication; proton pump inhibitor; rabeprazole; omeprazole; lansoprazole; pantoprazole; esomeprazole; CYTOCHROME-P450; ENZYMES; 2C9; 1-WEEK TRIPLE THERAPY; RANDOMIZED OPEN TRIAL; ERADICATION RATE; CURE RATES; OMEPRAZOLE METABOLISM; GENOTYPIC DIFFERENCES; DRUG-METABOLISM; DUAL THERAPY; RABEPRAZOLE;
D O I：
10.2174/138920012803341393
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism of individual PPIs to different extents. Although PPIs are highly effective as a class, differences in their pharmacokinetics, such as bioavailability and metabolism, may translate into differences in clinical outcomes. In Helicobacter pylori infection, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole but no with rabeprazole.
引用
收藏
页码：1303 / 1312
页数：10
相关论文
共 50 条
  • [31] Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan
    Dojo, M
    Azuma, T
    Saito, T
    Ohtani, M
    Muramatsu, A
    Kuriyama, M
    DIGESTIVE AND LIVER DISEASE, 2001, 33 (08) : 671 - 675
  • [32] THE EFFECT OF CYP2C19 POLYMORPHISMS ON CONCOMITANT THERAPY WITH DIFFERENT PROTON PUMP INHIBITORS FOR HELICOBACTER PYLORI ERADICATION
    Hong, J.
    Shu, X.
    Zhu, Y.
    Wang, A.
    Xie, C.
    Lu, N.
    HELICOBACTER, 2015, 20 : 74 - 74
  • [33] The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole
    Lee, Jeong Hoon
    Jung, Hwoon-Yong
    Choi, Kee Don
    Song, Ho June
    Lee, Gin Hyug
    Kim, Jin-Ho
    GUT AND LIVER, 2010, 4 (02) : 201 - 206
  • [34] The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis
    Fu, Juan
    Sun, Chang-Feng
    He, Hong-Yan
    Ojha, Suvash Chandra
    Shi, Han
    Deng, Cun-Liang
    Sheng, Yun-Jian
    PHARMACOGENOMICS, 2021, 22 (13) : 859 - 879
  • [35] A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism
    Miyoshi, M
    Mizuno, M
    Ishiki, K
    Nagahara, Y
    Maga, T
    Torigoe, T
    Nasu, J
    Okada, H
    Yokota, K
    Oguma, K
    Tsuji, T
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (07) : 723 - 728
  • [36] CYP2C19 genotypes and Helicobacter pylori eradication
    Sheu, Bor-Shyang
    Fock, Kwong-Ming
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (08) : 1163 - 1163
  • [37] Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
    Furuta, T
    Shirai, N
    Takashima, M
    Xiao, F
    Hanai, H
    Sugimura, H
    Ohashi, K
    Ishizaki, T
    Kaneko, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 158 - 168
  • [38] Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers
    Pawlowska, M.
    Bogiel, M.
    Duda, J.
    Sieradzki, E.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (06) : 699 - 705
  • [39] Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers
    M. Pawlowska
    M. Bogiel
    J. Duda
    E. Sieradzki
    European Journal of Clinical Pharmacology, 2015, 71 : 699 - 705
  • [40] CYP2C19 genotypes in Germany and influence on treatment of Helicobacter pylori infection
    Kirsch, C
    Schneider-Brachert, W
    Grossmann, D
    Stolte, M
    Lehn, N
    Miehlke, S
    GASTROENTEROLOGY, 2003, 124 (04) : A180 - A180
12345